Öйú365betÖÐÎĹÙÍø

Tuberculosis (TB) remains a relentless global threat as the world’s top infection killer. The urgent need for innovative strategies to combat drug resistance and develop effective treatments persists, as the World Health Organization reports a staggering 30,000 new TB infections and nearly 4,500 deaths worldwide each day. Two promising strategies focus on inhibiting coenzyme A (CoA) biosynthesis and targeting essential bacterial pathways.

Join Cynthia Dowd of George Washington University as she explores novel CoA biosynthesis inhibitors, specifically targeting phosphopantothenoylcysteine synthetase (PPCS), a key enzyme in Mycobacterium tuberculosis (Mtb). Learn how these inhibitors could shape future TB treatments by disrupting vital metabolic processes. Then, hear from Tanya Parish of the University of Washington School of Medicine and Seattle Children’s Research Institute as she discusses strategies for discovering new TB drugs. Discover how microbiology, high-throughput screening, and medicinal chemistry converge to identify essential pathways and combat drug resistance.

Register now to stay at the forefront of drug discovery and gain critical insights into cutting-edge TB research and the fight against drug-resistant strains. This ACS Webinar is moderated by Sandhya Ganesan of IISER Thiruvananthapuram in India and is co-produced by ACS Publications.

What You Will Learn:

• How Mycobacterium tuberculosis synthesizes CoA and why it’s a promising drug target
• The rationale behind designing novel PPCS inhibitors and their impact on TB treatment
• How essential bacterial pathways are identified and targeted for drug discovery
• Why Mycobacterium tuberculosis develops resistance and how to overcome this challenge